S
Stefan Vitko
Researcher at Charles University in Prague
Publications - 86
Citations - 4797
Stefan Vitko is an academic researcher from Charles University in Prague. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 28, co-authored 86 publications receiving 4479 citations. Previous affiliations of Stefan Vitko include Novartis.
Papers
More filters
Journal ArticleDOI
Reduced exposure to calcineurin inhibitors in renal transplantation.
Henrik Ekberg,Helio Tedesco-Silva,Alper Demirbas,Stefan Vitko,Björn Nashan,A. Gurkan,Raimund Margreiter,Christian Hugo,Josep M. Grinyó,Ulrich Frei,Yves Vanrenterghem,Pierre Daloze,Philip F. Halloran +12 more
TL;DR: In this paper, the authors evaluated the efficacy and relative toxic effects of four immunosuppressive regimens: cyclosporine, mycophenolate mofetil, and corticosteroids.
Journal ArticleDOI
Calcineurin Inhibitor Minimization in the Symphony Study: Observational Results 3 Years after Transplantation
Henrik Ekberg,Corrado Bernasconi,Helio Tedesco-Silva,Stefan Vitko,Christian Hugo,Alper Demirbas,R Reyes Acevedo,Josep M. Grinyó,Ulrich Frei,Yves Vanrenterghem,Pierre Daloze,Philip F. Halloran +11 more
TL;DR: In the Symphony study, the largest ever prospective study in de novo kidney transplantation, over 3 years, daclizumab induction, MMF, steroids and low‐dose tacrolimus proved highly efficacious, without the negative effects on renal function commonly reported for standard CNI regimens
Journal ArticleDOI
Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data
Greg Knoll,Madzouka B. Kokolo,Ranjeeta Mallick,Andrew H. Beck,Chieny Buenaventura,Robin Ducharme,Rashad S. Barsoum,Corrado Bernasconi,Tom Blydt-Hansen,Henrik Ekberg,Claudia Rosso Felipe,John Firth,Lorenzo Gallon,M. Gelens,Denis Glotz,Jan Gossmann,Markus Guba,Ahmed Morsy,Rebekka Salgo,Earnst H Scheuermann,Helio Tedesco-Silva,Stefan Vitko,Christopher J.E. Watson,Dean Fergusson +23 more
TL;DR: Sirolimus was associated with a reduction in the risk of malignancy and non-melanoma skin cancer in transplant recipients and the use of this drug does not seem warranted for most patients with kidney transplant.
Journal ArticleDOI
Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies.
Stefan Vitko,H. Tedesco,Josette Eris,Julio Pascual,J. Whelchel,John C. Magee,Scott B. Campbell,Giovanni Civati,Bernard Bourbigot,Gentil Alves Filho,John Leone,Valter Duro Garcia,Paolo Rigotti,Ronaldo de Matos Esmeraldo,Vincenzo Cambi,Tomas Haas,Annette Jappe,Peter Bernhardt,Johanna Geissler,Nathalie Cretin +19 more
TL;DR: Concentration‐controlled everolimus with low‐exposure CsA provided effective protection against rejection with good renal function in de novo renal transplant patients.
Journal ArticleDOI
Three-Year Outcomes From BENEFIT-EXT: A Phase III Study of Belatacept Versus Cyclosporine in Recipients of Extended Criteria Donor Kidneys
J. O. Medina Pestana,Josep M. Grinyó,Yves Vanrenterghem,Thomas Becker,Josep M. Campistol,Sander Florman,Valter Duro Garcia,Nassim Kamar,Peter Lang,R.C. Manfro,Pablo U. Massari,M Rial,Mark A. Schnitzler,Stefan Vitko,T. Duan,A. Block,M. B. Harler,Antoine Durrbach +17 more
TL;DR: In conclusion, at 3 years after transplantation, immunosuppression with belatacept resulted in similar patient survival, graft survival and acute rejection, with better renal function compared with cyclosporine.